Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Fry Website

Terry J. Fry, M.D.

Selected Publications

1)  Donahue RN, Duncan BB, Fry TJ, Jones B, Bachovchin WW, Kiritsy CP, Lai JH, Wu W, Zhao P, Liu Y, Tsang K, Hodge JW.
A pan inhibitor of DASH family enzymes induces immunogenic modulation and sensitizes murine and human carcinoma cells to antigen-specific cytotoxic T lymphocyte killing: implications for combination therapy with cancer vaccines.
Vaccine. [Epub ahead of print], 2014.
2)  Capitini CM, Nasholm NM, Chien CD, Larabee SM, Qin H, Song YK, Klover PJ, Hennighausen L, Khan J, Fry TJ.
Absence of STAT1 in donor-derived plasmacytoid dendritic cells results in increased STAT3 and attenuates murine GVHD.
Blood. 2014.
3)  Orentas RJ, Nordlund J, He J, Sindiri S, Mackall C, Fry TJ, Khan J.
Bioinformatic description of immunotherapy targets for pediatric T-cell leukemia and the impact of normal gene sets used for comparison.
Front Oncol. 4: 134, 2014.
4)  Shand JC, Qin H, Nasholm N, Capitini CM, Fry TJ.
Minor antigen distribution predicts site-specific graft-versus-tumor activity of adoptively transferred, minor antigen-specific CD8 T Cells.
Biol. Blood Marrow Transplant. 20: 26-36, 2014.
5)  Jacoby E, Chien CD, Fry TJ.
Murine models of acute leukemia: important tools in current pediatric leukemia research.
Front Oncol. 4: 95, 2014.
6)  Duncan BB, Highfill SL, Qin H, Bouchkouj N, Larabee S, Zhao P, Woznica I, Liu Y, Li Y, Wu W, Lai JH, Jones B, Mackall CL, Bachovchin WW, Fry TJ.
A Pan-Inhibitor of DASH Family Enzymes Induces Immune-mediated Regression of Murine Sarcoma and Is a Potent Adjuvant to Dendritic Cell Vaccination and Adoptive T-cell Therapy.
J. Immunother. 36: 400-11, 2013.
7)  Capitini CM, Nasholm NM, Duncan BB, Guimond M, Fry TJ.
Graft-versus-host disease impairs vaccine responses through decreased CD4+ and CD8+ T cell proliferation and increased perforin-mediated CD8+ T cell apoptosis.
J. Immunol. 190: 1351-9, 2013.
8)  Fry TJ, Mackall CL.
T-cell adoptive immunotherapy for acute lymphoblastic leukemia.
Hematology Am Soc Hematol Educ Program. 2013: 348-53, 2013.
9)  Walsh MP, Duncan B, Larabee S, Krauss A, Davis JP, Cui Y, Kim SY, Guimond M, Bachovchin W, Fry TJ.
Val-BoroPro Accelerates T Cell Priming via Modulation of Dendritic Cell Trafficking Resulting in Complete Regression of Established Murine Tumors.
PLoS ONE. 8: e58860, 2013.
10)  Salit RB, Fowler DH, Wilson WH, Dean RM, Pavletic SZ, Dunleavy K, Hakim F, Fry TJ, Steinberg SM, Hughes TE, Odom J, Bryant K, Gress RE, Bishop MR.
Dose-adjusted EPOCH-rituximab combined with fludarabine provides an effective bridge to reduced-intensity allogeneic hematopoietic stem-cell transplantation in patients with lymphoid malignancies.
J. Clin. Oncol. 30: 830-6, 2012.
11)  Shah NN, Bacher U, Fry T, Calvo KR, Stetler-Stevenson M, Arthur DC, Kurlander R, Baird K, Wise B, Giralt S, Bishop M, Hardy NM, Wayne AS.
Myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation: diagnostic and therapeutic challenges.
Am. J. Hematol. 87: 916-22, 2012.
12)  Baird K, Fry TJ, Steinberg SM, Bishop MR, Fowler DH, Delbrook CP, Humphrey JL, Rager A, Richards K, Wayne AS, Mackall CL.
Reduced-Intensity Allogeneic Stem Cell Transplantation in Children and Young Adults with Ultrahigh-Risk Pediatric Sarcomas.
Biol Blood Marrow Transplant. 18: 698-707, 2012.
13)  Dubrovsky L, McCarter RJ, Fry TJ, Wong E, Cheng Y, Perez-Albuerne ED.
Analysis of pediatric autologous PBSC apheresis and transplant: Age is a major factor affecting post-transplant toxicity.
Pediatr Blood Cancer. 59: 301-5, 2011.
14)  Dubrovsky L, Wong EC, Perez-Albuerne E, Loechelt B, Kamani N, Sande J, Mintz K, Paul W, Luban NL, Rood BR, Fry T.
CD34⁺ collection efficiency as a function of blood volumes processed in pediatric autologous peripheral blood stem cell collection.
J Clin Apher. 26: 131-7, 2011.
15)  Paolino K, Sande J, Perez E, Loechelt B, Jantausch B, Painter W, Anderson M, Tippin T, Lanier ER, Fry T, DeBiasi RL.
Eradication of disseminated adenovirus infection in a pediatric hematopoietic stem cell transplantation recipient using the novel antiviral agent CMX001.
J. Clin. Virol. 50: 167-70, 2011.
16)  Capitini CM, Davis JP, Larabee SM, Herby S, Nasholm NM, Fry TJ.
Extracorporeal photopheresis attenuates murine graft-versus-host disease via bone marrow-derived interleukin-10 and preserves responses to dendritic cell vaccination.
Biol. Blood Marrow Transplant. 17: 790-9, 2011.
17)  Mackall CL, Fry TJ, Gress RE.
Harnessing the biology of IL-7 for therapeutic application.
Nat. Rev. Immunol. 11: 330-42, 2011.
18)  Fry TJ.
Self-enabling T cells.
Blood. 117: 6742-3, 2011.
19)  Fry TJ, Lankester AC.
Cancer immunotherapy: will expanding knowledge lead to success in pediatric oncology?.
Hematol. Oncol. Clin. North Am. 24: 109-27, 2010.
20)  Fry TJ.
Expanding options to improve outcomes following hematopoietic stem cell transplantation.
Pediatr Blood Cancer. 55: 1043-4, 2010.
21)  Voss CY, Fry TJ, Coppes MJ, Blajchman MA.
Extending the horizon for cell-based immunotherapy by understanding the mechanisms of action of photopheresis.
Transfus Med Rev. 24: 22-32, 2010.
22)  Fry TJ, Willasch A, Bader P.
The graft-versus-tumor effect in pediatric malignancy.
Pediatr. Clin. North Am. 57: 67-81, 2010.
23)  Fry TJ, Shand JL, Milliron M, Tasian SK, Mackall CL.
Antigen loading of DCs with irradiated apoptotic tumor cells induces improved anti-tumor immunity compared to other approaches.
Cancer Immunol. Immunother. 58: 1257-64, 2009.
24)  Mackall C, Fry T, Gress R, Peggs K, Storek J, Toubert A.
Background to hematopoietic cell transplantation, including post transplant immune recovery.
Bone Marrow Transplant. 44: 457-62, 2009.
25)  Capitini CM, Herby S, Milliron M, Anver MR, Mackall CL, Fry TJ.
Bone marrow deficient in IFN-{gamma} signaling selectively reverses GVHD-associated immunosuppression and enhances a tumor-specific GVT effect.
Blood. 113: 5002-9, 2009.
26)  Capitini CM, Fry TJ, Mackall CL.
Cytokines as Adjuvants for Vaccine and Cellular Therapies for Cancer.
Am J Immunol. 5: 65-83, 2009.
27)  Fry TJ.
Is a little GVHD a good thing?.
Blood. 113: 6274-5, 2009.
28)  Dromi SA, Walsh MP, Herby S, Traughber B, Xie J, Sharma KV, Sekhar KP, Luk A, Liewehr DJ, Dreher MR, Fry TJ, Wood BJ.
Radiofrequency ablation induces antigen-presenting cell infiltration and amplification of weak tumor-induced immunity.
Radiology. 251: 58-66, 2009.
29)  Capitini CM, Derdak J, Hughes MS, Love CP, Baird K, Mackall CL, Fry TJ.
Unusual sites of extraskeletal metastases of Ewing sarcoma after allogeneic hematopoietic stem cell transplantation.
J. Pediatr. Hematol. Oncol. 31: 142-4, 2009.
30)  Sportès C, Hakim FT, Memon SA, Zhang H, Chua KS, Brown MR, Fleisher TA, Krumlauf MC, Babb RR, Chow CK, Fry TJ, Engels J, Buffet R, Morre M, Amato RJ, Venzon DJ, Korngold R, Pecora A, Gress RE, Mackall CL.
Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets.
J. Exp. Med. 205: 1701-14, 2008.
31)  Dean RM, Fry T, Mackall C, Steinberg SM, Hakim F, Fowler D, Odom J, Foley J, Gress R, Bishop MR.
Association of serum interleukin-7 levels with the development of acute graft-versus-host disease.
J. Clin. Oncol. 26: 5735-41, 2008.
32)  Wiener LS, Steffen-Smith E, Battles HB, Wayne A, Love CP, Fry T.
Sibling stem cell donor experiences at a single institution.
Psychooncology. 17: 304-7, 2008.
33)  Chung YJ, Choi CW, Slape C, Fry T, Aplan PD.
Transplantation of a myelodysplastic syndrome by a long-term repopulating hematopoietic cell.
Proc. Natl. Acad. Sci. U.S.A. 105: 14088-93, 2008.
34)  Wiener LS, Steffen-Smith E, Fry T, Wayne AS.
Hematopoietic stem cell donation in children: a review of the sibling donor experience.
J Psychosoc Oncol. 25: 45-66, 2007.
35)  Fluur C, De Milito A, Fry TJ, Vivar N, Eidsmo L, Atlas A, Federici C, Matarrese P, Logozzi M, Rajnavölgyi E, Mackall CL, Fais S, Chiodi F, Rethi B.
Potential role for IL-7 in Fas-mediated T cell apoptosis during HIV infection.
J. Immunol. 178: 5340-50, 2007.
36)  Krupica T, Fry TJ, Mackall CL.
Autoimmunity during lymphopenia: a two-hit model.
Clin. Immunol. 120: 121-8, 2006.
37)  Rosenberg SA, Sportès C, Ahmadzadeh M, Fry TJ, Ngo LT, Schwarz SL, Stetler-Stevenson M, Morton KE, Mavroukakis SA, Morre M, Buffet R, Mackall CL, Gress RE.
IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells.
J. Immunother. 29: 313-9, 2006.
38)  Snyder KM, Mackall CL, Fry TJ.
IL-7 in allogeneic transplant: clinical promise and potential pitfalls.
Leuk. Lymphoma. 47: 1222-8, 2006.
39)  Melchionda F, Fry TJ, Milliron MJ, McKirdy MA, Tagaya Y, Mackall CL.
Adjuvant IL-7 or IL-15 overcomes immunodominance and improves survival of the CD8+ memory cell pool.
J. Clin. Invest. 115: 1177-87, 2005.
40)  Guimond M, Fry TJ, Mackall CL.
Cytokine signals in T-cell homeostasis.
J. Immunother. 28: 289-94, 2005.
41)  Fry TJ, Mackall CL.
Immune reconstitution following hematopoietic progenitor cell transplantation: challenges for the future.
Bone Marrow Transplant. 35 Suppl 1: S53-7, 2005.
42)  Fry TJ, Mackall CL.
The many faces of IL-7: from lymphopoiesis to peripheral T cell maintenance.
J. Immunol. 174: 6571-6, 2005.
43)  Al-Shami A, Spolski R, Kelly J, Fry T, Schwartzberg PL, Pandey A, Mackall CL, Leonard WJ.
A role for thymic stromal lymphopoietin in CD4(+) T cell development.
J. Exp. Med. 200: 159-68, 2004.
44)  Melchionda F, McKirdy MK, Medeiros F, Fry TJ, Mackall CL.
Escape from immune surveillance does not result in tolerance to tumor-associated antigens.
J. Immunother. 27: 329-38, 2004.
45)  Fry TJ, Sinha M, Milliron M, Chu YW, Kapoor V, Gress RE, Thomas E, Mackall CL.
Flt3 ligand enhances thymic-dependent and thymic-independent immune reconstitution.
Blood. 104: 2794-800, 2004.
46)  Moniuszko M, Fry T, Tsai WP, Morre M, Assouline B, Cortez P, Lewis MG, Cairns S, Mackall C, Franchini G.
Recombinant interleukin-7 induces proliferation of naive macaque CD4+ and CD8+ T cells in vivo.
J. Virol. 78: 9740-9, 2004.
47)  Fry TJ, Moniuszko M, Creekmore S, Donohue SJ, Douek DC, Giardina S, Hecht TT, Hill BJ, Komschlies K, Tomaszewski J, Franchini G, Mackall CL.
IL-7 therapy dramatically alters peripheral T-cell homeostasis in normal and SIV-infected nonhuman primates.
Blood. 101: 2294-9, 2003.
48)  Khaled AR, Li WQ, Huang J, Fry TJ, Khaled AS, Mackall CL, Muegge K, Young HA, Durum SK.
Bax deficiency partially corrects interleukin-7 receptor alpha deficiency.
Immunity. 17: 561-73, 2002.
49)  Fry TJ, Mackall CL.
Current concepts of thymic aging.
Springer Semin. Immunopathol. 24: 7-22, 2002.
50)  Sinha ML, Fry TJ, Fowler DH, Miller G, Mackall CL.
Interleukin 7 worsens graft-versus-host disease.
Blood. 100: 2642-9, 2002.
51)  Fry TJ, Mackall CL.
Interleukin-7 and immunorestoration in HIV: beyond the thymus.
J. Hematother. Stem Cell Res. 11: 803-7, 2002.
52)  Fry TJ, Mackall CL.
Interleukin-7: from bench to clinic.
Blood. 99: 3892-904, 2002.
53)  Fry TJ, Connick E, Falloon J, Lederman MM, Liewehr DJ, Spritzler J, Steinberg SM, Wood LV, Yarchoan R, Zuckerman J, Landay A, Mackall CL.
A potential role for interleukin-7 in T-cell homeostasis.
Blood. 97: 2983-90, 2001.
54)  Fry TJ, Christensen BL, Komschlies KL, Gress RE, Mackall CL.
Interleukin-7 restores immunity in athymic T-cell-depleted hosts.
Blood. 97: 1525-33, 2001.
55)  Fry TJ, Mackall CL.
Interleukin-7: master regulator of peripheral T-cell homeostasis?.
Trends Immunol. 22: 564-71, 2001.
56)  Fry TJ, Mackall CL.
What limits immune reconstitution in HIV infection? Divergent tools converge on thymic function.
AIDS. 15: 1881-2, 2001.
Click Here to View Collapsed Bibliography.

This page was last updated on 8/11/2014.